Core Viewpoint - The flu season has intensified, leading to increased consultations and concerns about the effectiveness of the antiviral drug Oseltamivir, particularly regarding its resistance rates [1]. Group 1: Efficacy of Oseltamivir - Current data suggests that while there may be a slight decrease in sensitivity of Oseltamivir against H1N1 and H3N2 strains, the resistance rate is not significantly high, with WHO reporting it at under 2% [1]. - In China, the latest monitoring indicates that 3.99% of A(H1N1)pdm09 strains show reduced sensitivity to neuraminidase inhibitors, but this should not cause excessive alarm [1]. - Oseltamivir remains a crucial first-line treatment for influenza despite some cases of reduced sensitivity due to improper use of the medication [1]. Group 2: Treatment Recommendations - If a patient does not show improvement after 48 hours of taking Oseltamivir, it may be necessary to consider potential resistance and conduct sensitivity testing [1]. - Alternatives to Oseltamivir include RNA polymerase inhibitors such as Baloxavir, Laninamivir (for H1N1), and Favipiravir (for cases where other antivirals are ineffective) [2]. - For severe cases or patients unable to take oral medication, inhaled drugs like Zanamivir or intravenous options like Peramivir can be utilized [2]. Group 3: Guidelines for Use - It is advised that patients with symptoms should use antiviral medications under the guidance of healthcare professionals to ensure proper usage [2]. - The standard treatment course for Oseltamivir is 5 days, with a recommended dosage of 75mg twice daily for adults and adolescents over 13 [2]. - Vaccination against influenza is emphasized as an effective preventive measure, ideally completed before October each year to reduce the risk of complications and resistance [2].

Core Insights - The flu activity in China is rapidly increasing, with the overall flu epidemic at a moderate level, and Beijing has entered the peak period of flu [1][3] Group 1: Flu Situation and Monitoring - The Beijing Municipal Health Commission reported that the flu has reached its peak, with the circulating strain being H3N2, which is still below historical peaks compared to previous seasons [3] - A "three-medical linkage" monitoring and scheduling mechanism has been established by the Beijing Municipal Health Commission, Medical Insurance Bureau, and Drug Administration to ensure a balanced supply and demand of flu medications [3] Group 2: Vaccination and Preventive Measures - The flu vaccine in Beijing will continue to be available for self-paid vaccination until the end of February 2026, with various methods for citizens to make appointments [3] - Preventive medication is recommended primarily for high-risk individuals who have not been vaccinated or are in close contact with confirmed cases, with a recommended usage window of within 48 hours post-exposure [5] Group 3: Pediatric Care and Hospital Response - The Beijing Children's Hospital has seen a significant increase in respiratory disease consultations since November, with a 20% rise in patient visits noted in the third week of November [7] - The hospital has increased its medical staff by approximately 15% and is providing online consultations to reduce the risk of cross-infection during peak times [7][8] Group 4: Future Actions - The Beijing Municipal Health Commission will continue to closely monitor the disease's spread and ensure medical service support for children's respiratory diseases [9]

Core Viewpoint - The flu poses significant public health risks, especially during the peak travel season coinciding with the flu season, necessitating effective antiviral treatments and preventive measures [1][5][7]. Market Demand - The optimization of China's exit and entry policies has led to a surge in outbound travel, with projections indicating over 155 million outbound trips by 2025, contributing to the global spread of flu [5]. - The World Health Organization estimates around 1 billion seasonal flu cases annually, resulting in 290,000 to 650,000 deaths, highlighting the severity of flu outbreaks [5]. - The overlap of the winter-spring travel peak and flu season raises concerns for public health systems, particularly for vulnerable populations [5][6]. Treatment Options - Antiviral treatment is crucial for flu management, with the most effective results achieved within 48 hours of symptom onset [1][7]. - The primary antiviral medications available in China include Oseltamivir and Baloxavir Marboxil, both effective against influenza A and B [1][8]. - The expert consensus emphasizes vaccination as the primary preventive measure against flu, particularly for high-risk groups [7][8]. Competitive Landscape - The flu medication market in China has become increasingly competitive, especially after the expiration of Oseltamivir's patent in 2016, leading to a surge in generic versions [2][9]. - As of November 2025, there are nearly 140 approved products related to Oseltamivir in China, indicating a highly saturated market [9]. - Baloxavir Marboxil, a second-generation flu treatment, has gained market traction since its approval in 2021, with sales expected to exceed 1.5 billion yuan by 2024 [10][11]. Market Growth Potential - The Chinese flu medication market was valued at 10.74 billion yuan in 2023, reflecting a year-on-year growth of 197.51% [11]. - Projections indicate a compound annual growth rate of 20.2% from 2024 to 2028, with the market potentially reaching 26.9 billion yuan by 2028 [11].

Investment Rating - The industry investment rating is "Overweight (Maintain)" [1] Core Viewpoints - The report highlights that the flu season in China may arrive earlier this year, with different circulating strains compared to last year, indicating a potential increase in demand for antiviral medications and vaccines related to respiratory diseases [4][6] - The report emphasizes the importance of monitoring the market for respiratory disease medications, particularly antiviral drugs and flu vaccines, due to the anticipated rise in flu cases [5][6] Summary by Relevant Sections Industry Overview - The report focuses on the pharmaceutical and biotechnology industry, particularly in the context of respiratory diseases and flu medications [1] Market Trends - The flu season is expected to start earlier this year, with the predominant strain being H3N2, which may lead to lower immunity in the population compared to last year [4] - The report notes that acute respiratory infections pose a significant health risk, especially with the changing virus strains [4] Investment Recommendations - The report suggests focusing on companies involved in respiratory disease medications such as Teva Pharmaceutical, Zhongsheng Pharmaceutical, Yiling Pharmaceutical, and others [6] - It also recommends paying attention to flu vaccine manufacturers like Hualan Biological Engineering and Baike Biological [6]

中新网杭州7月6日电(张煜欢)夏季高温潮湿的环境为各类病毒和细菌的滋生提供了温床，而人们出行游 玩时，与自然环境的亲密接触也增加了感染病毒的可能。专家提醒，蜱虫在山林、乡村较为常见，其通 常会附着在人体皮肤上，通过吸血传播多种病原体，一旦被其叮咬，就有可能引发诸如发热伴血小板减 少综合征等急性传染病，这些疾病起病急，对身体健康造成严重威胁。在夏季出行时，一定要做好防护 措施，避免被蜱虫叮咬。 专家表示，该疾病初期起病急，多高热，伴乏力、食欲不振、恶心、呕吐等，部分病例有肌肉酸痛、腹 泻，少数有神志淡漠。极期可与发热期重叠，持续高热，极度乏力、消化道症状明显加重。重症病例可 出现皮肤瘀斑、消化道出血、肺出血、烦躁不安、谵妄，甚至抽搐、昏迷，可因循环衰竭、呼吸衰竭、 出血等死亡。 与家属沟通后，医生紧急联系疾控部门进行新型布尼亚病毒确诊检测，并收治吴奶奶入院，做好单间隔 离。医院肝病感染科副主任医师方莉得知患者情况后，立即仔细对其进行床边全面查体，发现她的腹 部、会阴部可见部分散在红色皮疹，未见蜱虫虫体。 不久前，73岁的吴奶奶(化名)被家人搀扶着来到浙大邵逸夫医院绍兴院区。"医生，我已经发烧4天，浑 身没力气， ...